The specific features of using a rivastigmine transdermal formulation in Alzheimer’s disease
Cholinergic deficiency associated mainly with the degeneration of neurons in the nucleus basalis of Meynert is one of the key factors of the development of cognitive impairments in Alzheimer’s disease (AD). Cholinesterase inhibitors are used to treat mild and moderate dementia in AD. However, the wi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2012-09-01
|
| Series: | Nevrologiâ, Nejropsihiatriâ, Psihosomatika |
| Subjects: | |
| Online Access: | https://nnp.ima-press.net/nnp/article/view/153 |